S
ince the introduction of aminopterin and subsequently methotrexate (MTX) into the clinic, many promising analogs have been developed and their use in combination chemotherapy has become a standard mode of treatment for a wide range of malignancies. The basis of this approach is that drugs with different mechanisms of action or targets when combined may allow additive or synergistic effects on the tumor. This offers a broader range of efficacy against heterogeneous tumor populations and may prevent or slow the development of drug resistance.
Pemetrexed is a novel folate antagonist that exerts its activity through the inhibition of multiple folate coenzyme-dependent enzyme targets involved in the de novo purine and pyrimidine pathways. These enzymes include dihydrofolate reductase (DHFR), 1 thymidylate synthase (TS), and glycinamide ribonucleotide formyltransferase (GARFT). 2 Phase II and III studies have shown that pemetrexed has promising antitumor activity against a variety of solid tumor types including mesothelioma, nonsmall-cell lung carcinoma, and colon, pancreatic, and breast cancers. 2, 3 Additionally, xenograft studies with human breast and non-small-cell lung carcinomas showed that combinations of pemetrexed with platinum compounds, MTX and 5-fluorouracil (5FU), produced additive or synergistic effects. 4 As with many chemotherapy regimens, a significant limitation to combination chemotherapy is myelosuppression. Furthermore, with combination chemotherapy the myelosuppressive effects may be additive. Standard treatments for reducing the duration and intensity of myelosuppression involve the use of recombinant growth factors and cytokine therapy, that is, G-CSF or GM-CSF. With the use of drug-resistant genes and retroviral gene transfer into hematopoietic stem cells (HSC), expression of resistant target enzymes in bone marrow is another strategy that has been considered for overcoming chemotherapy-induced myelosuppression. 5 The advantage to this approach is that it could provide resistance against specific chemotherapeutic agents, potentially allowing for higher dose intensity and/or shorter intervals between treatments. Furthermore, co-expression of multiple drug-resistant genes could provide myeloprotection against combination chemotherapies with two or more drugs.
Previously, we reported on the construction and characterization of a novel fusion gene consisting of a mutant dihyrofolate reductase (DHFR F/S) and mutant thymidylate synthase (TS G52S) cDNA, which when transduced into murine confers resistance to both MTX and 5FU. 1 As many malignancies, including breast cancer, 6 colon cancer, 7, 8 and head and neck cancer 9 are effectively treated with either or both of these agents, protection of hematopoietic precursor cells using this construct would allow safer use of these drugs and perhaps increased doses. We now report that this fusion gene also confers resistance to the multitargeted antifolate, pemetrexed, with additive resistance in murine bone marrow compared to cells expressing the individual mutant genes alone.
Methods

Materials
Pemetrexed and pemetrexed triglutamate were supplied by Eli Lilly (Indianapolis), and were also synthesized by Dr William Bornmann (Memorial Sloan-Kettering Cancer Center).
Cell lines and culture conditions
NIH 3T3 murine fibroblasts and GP-envAM12 cells 10 were cultured in Dulbecco's modified Eagle's medium (DMEM) containing high glucose (4.5 g/L) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 mg/ mL streptomycin, and 100 U/mL penicillin, and maintained at 371C/5% CO 2 .
Enzyme activities
DHFR activity was determined spectrophotometrically at 251C. Conversion of NADPH and FH 2 to NADP þ and FH 4 was monitored at 340 nm. 11 The assay mixture (final volume 1 mL) contained the enzyme, MATS assay buffer 12 (25 mM MES, 25 mM acetic acid, 50 mM Tris base, 100 mM sodium chloride) (pH 7.4), supplemented with 50 mg/mL BSA, 1 mM DTT, 50 mM b-mercaptoethanol, and 100 mM NADPH cofactor; FH 2 substrate (50 mM) was subsequently added after a 5 minute preincubation at 251C to initiate the reaction. TS activity was determined spectrophotometrically at 301C, where conversion of substrate (dUMP) and cofactor (CH 2 FH 4 ) to dTMP and FH 2 was monitored at 340 nm. 13 The assay mixture contained the enzyme, 50 mM Tris-HCl, pH 7.4, 25 mM MgCl 2 , 6.5 mM formaldehyde, 1 mM EDTA, 75 mM b-mercaptoethanol, and 100 mM dUMP substrate; 6-R-CH 2 FH 4 cofactor (100 mM, Eprova AG, Schaffhausen, Switzerland) was subsequently added after a 5 minute pre-incubation at 301C to initiate the 1 mL reaction.
Determination of K m values via steady-state kinetics
Michaelis constants (K m ) for the DHFR substrate H 2 folate were determined as described previously.
14 Briefly, using the above assay for DHFR activity, the initial velocity measurements of wtDHFR (5-10 nM) or DHFR-F/S-TS G52S (50 nM) were measured at a saturating concentration of cofactor NADPH (50 mM), while varying the concentration of H 2 folate over the range of 0.25-10 mM. K m values for the TS substrate dUMP were determined as described previously. 15 Using the above assay for TS activity, the initial velocity measurements of wtTS (200 nM), TS G52S (100 nM) or DHFR-F/S-TS G52S (80 nM) were measured at a saturating concentration of cofactor, 6-R-CH 2 H 4 folate (400 mM), while varying the concentration of dUMP over the range of 5-500 mM. Similarly, K m values for TS cofactor were determined at a saturating concentration of dUMP (500 mM), while varying the concentration of 6-R-CH 2 H 4 folate over the range of 2-500 mM.
Determination of K i values
Pemetrexed K i values using both the DHFR and TS assays were determined from steady-state inhibition reaction rates. For the determination of K i values, enzyme preparations were pre-incubated as indicated for DHFR or TS activities and the reactions initiated by adding a pre-mixture of pemetrexed (varying concentrations), with saturating levels of either FH 2 (100 mM) for DHFR evaluation or CH 2 FH 4 (400 mM) for TS evaluation. A competitive tight-binding mode of inhibition was assumed 16, 17 and an iterative fitting of the data to the Morrison equation was performed using the DA-TADNRP V2.31 program 18 to derive values for K i .
Generation of retroviral producer cell lines
SFG retroviral plasmid DNA constructs were transfected into GP-envAM12 cells using SuperFectt (QIAGEN Inc.). After 24 hours, transfected cells were exposed to 150 nM MTX or 750 mg/mL G418 for 10 days and individual colonies were isolated and expanded into producer cell lines. Titers of these producer cell lines were determined with NIH3T3 cells as target cells, and cell lines with high titers (10 5 -10 6 CFU/mL) were used for further experiments.
Transduction of NIH3T3 cells
NIH3T3 cells (1 Â 10 5 ) were plated in 100 mm dishes. After 24 h, the media was removed and replaced with filtered (0.45 mm) AM12 retroviral supernatant containing polybrene (8 mg/mL) at a multiplicity of infection (MOI) of 1 for an additional 24 h. Transduced 3T3 cells were selected for 3-4 days in either a medium containing 150 nM MTX (DHFR F/S) and 10% dialyzed FBS (dFBS) or in a medium containing 750 mg/mL G418 (Neo r ) and 10% FBS. After selection, the medium was changed to a non-drug-containing media containing 10% FBS, and 4-5 days later polyclonal populations of drugresistant colonies were used to perform clonogenic assays.
Clonogenic assay
Parental and retrovirally transduced NIH3T3 cells were seeded in duplicate in six-well plates at a concentration of 1000 cells/well. The following day, the medium was replaced with a medium containing pemetrexed at various concentrations in the presence of 10% dialyzed fetal bovine serum. After 7-10 days, colonies were stained with Crystal Violet and individual colonies of 50 or more cells were counted. IC 50 values were calculated from sigmoidaldose response curve fits of the data using the GraphPad Prism s software V3.0.
Mouse bone marrow transduction
Bone marrow cells from the long bones of 8-11-week-old male C57Bl/6J mice were harvested in IMDM medium supplemented with 20% FBS and filtered through a 70 mm nylon cell strainer to remove contaminating bone fragments, as previously described. The cells were then centrifuged at 1000 r.p.m. for 10 minutes followed by resuspension in IMDM media containing 10% WEHI-3B conditioned medium, 20% FBS, 50 ng/mL rSCF (Amgen), 50 ng/mL hIL-6 (Gibco), and 4 mg/mL polybrene. Cells were then added to T75-flasks containing 80% confluent AM12 producer cells previously irradiated at 1500 cGy. After 48 hours of coculture with AM12 producer cells, nonadherent bone marrow cells were harvested from each flask and counted to determine BM recovery and viability. Experiments with all cell lines were performed at the same time with the same source of bone marrow.
CFU-C assay
Bone marrow cells were collected from coculture and were plated in duplicate at 55,000 cells per 35 mm plate. Cells were plated in thymidine-phosphorylase-treated methylcellulose 19 culture medium (MethoCult GF M3434; Stem Cell Technologies Vancouver, BC, Canada) without and with pemetrexed at or above the concentration (100 nM) previously determined to be 100% lethal for mocktransduced mouse bone marrow-derived colonies (100 nM). The plates were stored at 371C in a 5% CO 2 incubator, and colonies of more than 50 cells were counted after 12 days. The surviving colonies in drug were expressed as a percentage of the control without drug.
CFU-C colony PCR. Individual colonies were harvested, resuspended in 500 mL of PBS, and centrifuged at 3000 r.p.m. for 10 minutes at room temperature. Cells were then resuspended in 30 mL of PCR lysis buffer (5 mM Tris, pH 8.1, 0.45% Tween 20, 100 mg/mL proteinase K) and incubated at 501C for 90 minutes, followed by a 5 minute proteinase K inactivation at 951C. A volume of 2 mL of each sample was used to amplify the transgene, as well as mouse b-actin as a control for DNA, in a 50 mL PCR reaction containing 200 mM dNTP, 300 ng each primer, 5 U Taq polymerase, and 1 Â Taq polymerase buffer containing 15 mM MgCl 2 . As described previously, 1 three sets of gene-specific primers were used to amplify a 628 bp segment of the DHFR F/S-TS G52S fusion gene, the entire 940 bp TS cDNA within the bicistronic TS G52S-IRES-DHFR F/S cDNA, and a 633 bp fragment within the neomycin phosphotransferase gene of all constructs containing the individual mutant or wild-type DHFR and TS genes. b-actin primers were used to amplify a 752 bp fragment within the genomic mouse bactin gene.
Results
The fusion protein has reduced affinity for pemetrexed (glu) 3 The purified DHFR F/S-TS G52S fusion protein, previously shown to retain the enzymatic properties of the individual mutant enzymes DHFR F/S and TS G52S, was evaluated for its affinity for pemetrexed. 1 As the polyglutamate form of this drug is the predominant intracellular form and has a much higher affinity for TS than the monoglutamate, 2 the triglutamate form of this compound, pemetrexed (glu) 3 , was used for the determination of inhibition constants (K i ). While there was no significant difference in affinity of the TS G52S portion of the fusion protein for pemetrexed (glu) 3 when compared to that of TS G52S and TS wt (K i ; 2.8, 2.5, 3.1 nM, respectively) (Table 1), the affinity of the DHFR F/S component of the fusion protein for pemetrexed (glu) 3 was reduced dramatically when compared to wtDHFR, with greater than 9000-fold reduction in K i (K i ; 8000 versus 0.86 nM), as was DHFR F/S with greater than 7000-fold reduction in K i (K i ; 6382 nM versus 0.86 nM) ( Table 2) .
Retroviral gene transfer of the DHFR F/S-TS G52S fusion into 3T3 cells confers additive resistance to pemetrexed
The NIH 3T3 cell lines were generated by retroviral transduction using supernatant from AM12 retroviral producer cell lines containing the retroviral constructs shown in Figure 1 . Following a 3-4-day selection and PCR analyses to verify the presence of the transduced gene (Fig 2) , clonogenic assays were performed and IC 50 values for pemetrexed were determined. DHFR and TS activity levels in each of the cell lines were determined as a control for differences in enzyme activity levels between the cell lines. These results 1 indicated that the DHFR and TS activity levels in cells expressing the DHFR F/S-TS G52S fusion protein were similar to the DHFR and TS activity levels in cells expressing DHFR F/S and TS G52S alone, respectively.
The IC 50 value for pemetrexed in cells expressing the DHFR F/S-TS G52S fusion protein was 163 nM. This value was five-to six-fold higher than cells expressing wtTS (23 nM) or wtDHFR (25 nM) (Fig 3) . These cells were also two-to three-fold more resistant to pemetrexed than cells expressing each of the individual mutant enzymes either alone, DHFR F/S (53 nM) or TS G52S (45 nM), or together from the bicistronic gene (40 nM). Neither wtDHFR (25 nM) or wtTS (23 nM) alone, when expressed in 3T3 cells, provided any protection against pemetrexed as compared to parental 3T3 cells (29 nM).
Retroviral gene transfer of DHFR F/S and TS G52S into mouse bone marrow protects from pemetrexed toxicity
The LD 100 for pemetrexed in hematopoietic progenitor cells was determined by performing a titration of nontransduced mouse bone marrow cells in methylcellulose with increasing doses of pemetrexed (Fig 4) . CFU-C Data are presented as the mean7standard deviations of at least three independent experiments. 13 Data are presented as the mean7 standard deviations of at least three independent experiments. assays were then performed using pemetrexed at and above the LD 100 .
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In CFU-C assays, dual expression of DHFR F/S and TS G52S resulted in significant colony formation over cells expressing the individual wt or mutant enzymes alone. At 300 nM pemetrexed, cells expressing either DHFR F/S or TS G52S alone had 44 and 79% resistant colonies, respectively (Table 3) , while cells expressing both enzymes together as a fusion or separately from the IRES element of the bicistronic gene had 104 and 84% resistant colonies, respectively. At 1000 nM pemetrexed, the number of colonies formed in bone marrow transduced with DHFR F/S-TS G52S and TS G52S-ires-DHFR F/S was 44 and 18%, respectively, and at 3000 nM pemetrexed, colony formation in these cells was 31 and 8% respectively. In contrast, there was little to no colony formation above 300 nM in bone marrow cells transduced to express the individual mutant and wt enzymes alone. In addition, PCR performed on cells cultured in the presence of drug indicated that 100% of drug-resistant colonies contained the gene of interest.
Discussion
The need for effective new drugs to treat cancers parallels the need for effective new strategies to manage the side effects of these drugs, with the most common side effect being myelosuppression. Gene transfer of drug resistance genes or resistant gene variants into hematopoietic stem cells is a strategy that is being investigated to increase bone marrow tolerance to chemotherapy. 5 Our laboratory has previously generated a variety of drug resistance genes, and combinations thereof, conferring resistance to antimetabolites such as MTX, trimetrexate, 5FU, raltitrexed, thymitaq, and cytosine arabinoside. 14, [20] [21] [22] [23] [24] In this study, we show that the transfer of a DHFR F/S-TS G52S fusion gene into hematopoietic progenitor cells results in resistance to a promising new antifolate, pemetrexed.
Resistance to pemetrexed was evaluated in NIH 3T3 cells and mouse bone marrow cells expressing the DHFR F/S-TS G52S fusion protein and compared to cells expressing the individual mutant or wild-type enzymes alone. Comparison was also performed against cells expressing both enzyme variants as separate proteins from a bicistronic gene. In clonogenic assays, NIH3T3 cells expressing each of the individual mutant enzymes alone, DHFR F/S or TS G52S, provided only a two-fold resistance to pemetrexed compared to parental 3T3 cells. Although the affinity (K i ) of purified DHFR F/S for pemetrexed (glu) 3 was dramatically reduced (47000-fold), this drug is known to mainly target TS; thus, only a two-fold decreased sensitivity in cells expressing DHFR F/S was not surprising. However, the two-fold decrease in sensitivity to pemetrexed in cells expressing TS G52S was not expected, since the affinity of purified TS G52S for pemetrexed (glu) 3 was the same as wtTS. Of importance, cells expressing the DHFR F/S-TS G52S fusion protein provided an additional three-to four-fold increase in resistance to pemetrexed compared to cells expressing either of the mutant enzymes alone or cells expressing both enzymes from the IRES element of the bicistronic gene.
In CFU-C assays, expression of both mutant enzymes together, DHFR F/S and TS G52S, from either the fusion gene or from the bicistronic gene provided significant colony survival at pemetrexed concentrations up to 3 mM compared to the expression of either of these mutant enzymes alone. These results are consistent with the additive effects of the fusion protein in conferring resistance to pemetrexed in clonogenic assays. Although expression of both mutant enzymes together from either The number of drug-resistant colonies are expressed as the percentage of gene-containing (PCR+) control colonies. Data are presented as the mean7SEM of at least three independent experiments. of the dual expression systems resulted in an increase in resistant colonies compared to expression of each mutant enzyme alone, colony formation from cells expressing the DHFR F/S-TS G52S fusion protein was consistently B20% higher than from cells expressing both mutant enzymes together from the bicistronic gene. The higher level of resistance generated by the fusion gene is the result of a higher DHFR F/S translation efficiency compared to that from the bicistronic gene, 1 and emphasizes the advantage of the fusion gene in maximizing gene expression for gene-transfer strategies. Interestingly, the additive effects against pemetrexed toxicity seen in bone marrow with expression from the bicistronic gene was not seen in clonogenic assays with 3T3 cells. This may be explained by observations made with other IRES elements in which efficiency of expression was tissue or cell-type specific. 25 Given the promising nature of pemetrexed as an anticancer drug, with significant antitumor activity in a wide range of solid tumors 26 and its synergistic effects when used in combination with other drugs, 27 it is likely that this drug will be used in many chemotherapy regimens soon. Thus, with recent advances in retroviral gene-transfer techniques, the myelosuppressive side effects from drugs such as pemetrexed may be alleviated with the use of drug-resistant genes such as the DHFR F/S-TS G52S fusion gene described here.
